People News: Affymax, Neogenix Oncology and ProBioGen AG

Share this article:

Affymax promoted Sylvia Wheeler to VP, corporate communications. Wheeler has more than 20 years of corporate communications and investor relations experience in the bioscience industry and is a member of the board of directors for the National Kidney Foundation Northwestern US Division.

Neogenix Oncology, Inc. has named Philip M. Arlen, MD its CEO. Arlen joined Neogenix as president and chief medical officer of the company in July 2008. Prior to 2008, he spent 11 years at the National Cancer Institute, USA, most recently as the director of the clinical research group for the Laboratory of Tumor Immunology and Oncology.

ProBioGen AG announced that Dr. Volker Sandig has been appointed to chief scientific officer (CSO) of the company. He will take over the duties of Dr. Uwe Marx, who will take an opportunity to lead an entrepreneurial innovation team at the Technical University Berlin.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in People Moves

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters